One Fin’s GRAIL Exit: A Timely Bailout

The timing, as it turned out, was impeccable. Or, if you’re a cynic, suspiciously so. GRAIL, a company focused on early cancer detection—a noble pursuit, naturally—had been riding a wave of optimism. More than 185,000 Galleri tests sold, revenue nudging toward $147 million. Impressive, if you ignored the rather substantial losses. Apparently, a lot of people were ignoring the losses. Or hoping they’d magically resolve themselves. The market has a habit of rewarding hope, until it doesn’t.








